Jørgensen will stay on as CEO temporarily for an undetermined period of time “to support a smooth transition” as the company looks for his replacement. Novo Nordisk’s value more than ...

In connection with the leadership transition, Lars Rebien Sørensen, Chair of the Novo Nordisk Foundation and former CEO of NVO, will initially join the company’s board as an observer ...

As part of the transition period, Lars Rebien Sørensen ... with operating profit ranging from approximately $5.4 to $6.3 billion. 2 “Serving as Novo Nordisk’s CEO for the past eight years has been a ...

Lars Fruergaard Jorgensen, who has headed the pharmaceutical company for eight years, will step down after a period to ...

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said Friday its chief executive was stepping down in the wake of "market challenges".

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Novo Nordisk, maker of weight loss drug Wegovy, says CEO Lars Fruergaard Jorgensen is leaving the company by "mutual agreement." ...

NVO said that the leadership transition was made in light of ... and share price have almost tripled. “Serving as Novo Nordisk’s CEO for the past eight years has been a privilege and an ...